Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2019
- Pages: 292
- Published: November 2019
- Report Code: GMDHC11479IDB
“Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) – Pipeline Review, H2 2019’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”
Scope
”
– The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
– The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects
– The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)”
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
“AB2 Bio Ltd
Abilita Bio Inc
Actinobac Biomed Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allergan Plc
Allosterix Ltd
Allysta Pharmaceuticals Inc
Apidel SA
Ascendia Pharmaceuticals LLC
Aurinia Pharmaceuticals Inc
Aviara Pharmaceuticals Inc
Avizorex Pharma SL
AxeroVision Inc
Azura Ophthalmics Ltd
Bessor Pharma LLC
BRIM Biotechnology Inc
Cambium Medical Technologies LLC
Cellix Bio Pvt Ltd
Dhp Korea Ltd
Dompe Farmaceutici SpA
Emerald Bioscience Inc
EyGen Ltd
Feldan Therapeutics Inc
GL Pharm Tech Corp
Glaukos Corp
Glia LLC
HanAll Biopharma Co Ltd
Huons Co Ltd
Huons Global Co Ltd
Icure Pharmaceutical Inc
Ipsen SA
IVIEW Therapeutics Inc
Kala Pharmaceuticals Inc
Kowa Co Ltd
Kukje Pharmaceutical Industry Co Ltd
Kv1.3 Therapeutics
Laboratoires Thea SA
Laboratorios Sophia SA de CV
Lee’s Pharmaceutical Holdings Ltd
LTT Bio-Pharma Co Ltd
Lubris Biopharma
Marinomed Biotech AG
MC2 Therapeutics AS
Merck & Co Inc
Mitotech SA
MyX Therapeutics Inc
Nanomerics Ltd
Neuroptika Inc
Novaliq GmbH
Novartis AG
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis SA
Ocunova LLC
OKYO Pharma Ltd
OncoNOx ApS
Oyster Point Pharma Inc
Palatin Technologies Inc
Panag Pharma Inc
Panoptes Pharma GesmbH
Pharmaleads SA
Pleryon Therapeutics Ltd
Proteris Biotech Inc
Quorum Innovations LLC
Redwood Pharma AB
RegeneRx Biopharmaceuticals Inc
RHNanopharmacuticals LLC
RiniSight Inc
Samjin Pharm Co Ltd
Santen Pharmaceutical Co Ltd
Senju Pharmaceutical Co Ltd
Serentrix LLC
Silk Technologies Ltd
Stuart Therapeutics Inc
Surface Pharmaceuticals Inc
Sylentis SAU
Tarsius Pharma Ltd
TearSolutions LLC
Tetra Bio-Pharma Inc
TopiVert Ltd
Vanda Pharmaceuticals Inc
Xigen SA
Yuyu Pharma Inc”
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.